Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.

Antimicrobial agents and chemotherapy - 1 Apr 2008

Desbois Delphine, Roquebert Bénédicte, Peytavin Gilles, Damond Florence, Collin Gilles, Bénard Antoine, Campa Pauline, Matheron Sophie, Chêne Geneviève, Brun-Vézinet Françoise, Descamps Diane

Abstract excerpt

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to HIV-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Inhibitory Concentration 50

Share to Lopinavir

Share to Pyrimidinones

Share to Saquinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 18227188
DOI: 10.1128/AAC.01284-07
PMCID: PMC2292533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.PMID 18227188Read ↗

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Semantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.Semantic proximity Read ↗

Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.Semantic proximity Read ↗

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Semantic proximity Read ↗

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.Semantic proximity Read ↗

Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.